Loading market dashboard
Coherus Oncology, Inc.
CHRSHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug in HCC and ongoing pivotal JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. CHRS's liquidity covers 2–3 quarters at current cash burn; further financing may be needed before pivotal clinical milestones.
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago.
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago.
– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif.
